Actemra

U.S. approves Roche’s Actemra arthritis drug

WASHINGTON, Jan 08 (Reuters) – The U.S. Food and Drug Administration has approved Roche Holding AG’s (ROG.VX) Actemra to treat rheumatoid arthritis, the company said on Friday.

The drug, made by Roche’s Genentech unit, is already approved for use in Europe and Japan and is expected by the company to become a blockbuster product.

The FDA approved the drug for treatment of adults with moderate to severe rheumatoid arthritis who do not respond well enough to another class of biotech drugs designed to block an inflammatory protein called tumor necrosis factor (TNF).

Actemra is an anti-interleukin-6 receptor antibody and works differently from TNF blockers such as Humira, sold by Abbott Laboratories (ABT.N), and Remicade, sold by Johnson & Johnson (JNJ.N).

Read More: http://www.reuters.com/article/idUSN0826524520100109

4 Comments
4 comments
  1. Sister FlareUp says:

    Actemra is given intravenously (through an IV). In the OPTION study, it was given every 4 weeks.

  2. Jennifer says:

    I am on Actemra here in Australia and LOVING it. I am now down from 20mg of pred to 10mg. Just considering going for a bike ride which I would not have been able to do previously :-)

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>